As of 2026-04-09, the EV/EBITDA ratio of Ligand Pharmaceuticals Inc (LGND) is 54.65. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LGND's latest enterprise value is 4,420.60 mil USD. LGND's TTM EBITDA according to its financial statements is 80.89 mil USD. Dividing these 2 quantities gives us the above LGND EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 14.6x - 26.8x | 16.5x |
| Forward P/E multiples | 18.5x - 35.6x | 27.0x |
| Fair Price | 45.46 - 107.64 | 65.84 |
| Upside | -78.2% - -48.3% | -68.4% |
| Date | EV/EBITDA |
| 2026-04-08 | 54.80 |
| 2026-04-07 | 53.92 |
| 2026-04-06 | 53.55 |
| 2026-04-02 | 52.56 |
| 2026-04-01 | 52.56 |
| 2026-03-31 | 52.57 |
| 2026-03-30 | 50.84 |
| 2026-03-27 | 51.54 |
| 2026-03-26 | 53.57 |
| 2026-03-25 | 53.78 |
| 2026-03-24 | 53.07 |
| 2026-03-23 | 52.75 |
| 2026-03-20 | 53.84 |
| 2026-03-19 | 55.24 |
| 2026-03-18 | 55.01 |
| 2026-03-17 | 55.37 |
| 2026-03-16 | 54.58 |
| 2026-03-13 | 53.38 |
| 2026-03-12 | 55.49 |
| 2026-03-11 | 57.89 |
| 2026-03-10 | 55.69 |
| 2026-03-09 | 54.67 |
| 2026-03-06 | 53.13 |
| 2026-03-05 | 54.20 |
| 2026-03-04 | 54.86 |
| 2026-03-03 | 53.70 |
| 2026-03-02 | 53.29 |
| 2026-02-27 | 52.24 |
| 2026-02-26 | 51.71 |
| 2026-02-25 | 50.54 |
| 2026-02-24 | 49.95 |
| 2026-02-23 | 48.63 |
| 2026-02-20 | 48.71 |
| 2026-02-19 | 49.29 |
| 2026-02-18 | 50.18 |
| 2026-02-17 | 49.58 |
| 2026-02-13 | 48.67 |
| 2026-02-12 | 48.13 |
| 2026-02-11 | 49.20 |
| 2026-02-10 | 49.46 |
| 2026-02-09 | 49.44 |
| 2026-02-06 | 50.30 |
| 2026-02-05 | 50.61 |
| 2026-02-04 | 52.25 |
| 2026-02-03 | 52.37 |
| 2026-02-02 | 52.15 |
| 2026-01-30 | 50.71 |
| 2026-01-29 | 51.47 |
| 2026-01-28 | 50.25 |
| 2026-01-27 | 51.55 |